New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
11:18 EDTABBV, JNJAbbVie patents affirmed as invalid by appeals court in suit with J&J unit
An appeals court affirmed a lower court finding that AbbVie (ABBV) patents involving antibodies that are useful for treating diseases are invalid. AbbVie has sued Janssen Biotech, a unit of Johnson & Johnson (JNJ), and Centocor Biologics for infringement of the patent claims. Reference Link
News For ABBV;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2015
10:05 EDTABBVAbbVie says has not reached a decision yet on celiac disease
Subscribe for More Information
09:54 EDTABBVAbbVie backs FY15 Humira sales forecast
Subscribe for More Information
09:53 EDTABBVAbbVie CEO says 'probably will' narrow guidance range
Subscribe for More Information
09:37 EDTABBVAbbVie sees Q3 operating revenue growth of about 20%, excluding forex
Subscribe for More Information
09:36 EDTABBVAbbVie sees Q3 adjusted EPS $1.05-$1.07, consensus $1.08
Subscribe for More Information
09:33 EDTABBVAbbVie sees FY15 Lupron sales roughly in line with 2014
AbbVie sees "modest growth" for Synthroid in FY15. Sees AndroGel sales "somewhat above" $500M for 2015.
09:21 EDTABBVAbbVie sees IMBRUVICA U.S. sales of about $1B for 2015
AbbVie Chairman and CEO Richard Gonzalez said the company continues to expect IMBRUVICA to drive U.S. sales of approximately $1B for the full calendar year 2015. Since the company completed the Pharmacyclics transaction, it has seen "additional positive data" and progress on its regulatory objectives, including readouts from two Phase 3 studies, HELIOS and RESONATE-2, noted Gonzalez during the company's Q2 earnings conference call.
07:56 EDTABBVAbbVie reports Q2 Viekira sales $385M, Q2 Imbruvica sales $234M
Subscribe for More Information
07:55 EDTABBVAbbVie reports Q2 Global Humira sales up 16.4% to $3.54B
Strong U.S. HUMIRA growth continued, driven by double-digit growth across all three major market categories, rheumatology, dermatology and gastroenterology. Reported international HUMIRA sales growth in the quarter was reduced by nearly 18 percent due to unfavorable foreign exchange. First-half 2015 international HUMIRA sales grew nearly 9 percent on an operational basis, consistent with planning expectations and the full year forecast for international HUMIRA sales growth of 9 to 10 percent on an operational basis. As noted last quarter, the first-quarter international operational growth rate of nearly 15 percent was favorably impacted by the timing of shipments in select markets. Consequently, sales growth in the second quarter was negatively impacted by shipment timing.
07:54 EDTABBVAbbVie backs FY15 adjusted EPS $4.10-$4.30, consensus $4.24
Subscribe for More Information
07:54 EDTABBVAbbVie reports Q2 adjusted EPS $1.08, consensus $1.06
Reports Q2 revenue $5.48B, consensus $5.62B
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
15:05 EDTABBVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include AbbVie (ABBV), consensus $1.06... Biogen (BIIB), consensus $4.10... Simon Property Group (SPG), consensus $2.36... State Street (STT), consensus $1.37... V.F. Corp. (VFC), consensus 36c... Johnson Controls (JCI), consensus 91c... American Airlines (AAL), consensus $2.60... Rockwell Collins (COL), consensus $1.30... Cabot Oil & Gas (COG), consensus 4c... Lear (LEA), consensus $2.48... Encana (ECA), consensus (15c).
14:55 EDTABBVAbbVie technical comments before earnings news
The stock is trading close to its life high at $71.60 ahead of earnings news. On a 2-year chart basis recent high price and the near-matching high from December of last year indicates shares are at major resistance. If the news is a bearish surprise, these two peaks in price could be construed as potential double top. Next supports below $70 would be at $68.50, $66.52, and $64.81. If the news is a bullish surprise, the life high could easily be taken out. An extension of the current bullish price channel in time yields a potential target at $75. Without overhead resistance, that level could be exceeded depending on the nature of the news.
13:56 EDTABBVEarnings Watch: AbbVie sees Q2 EPS $1.04-$1.06
Subscribe for More Information
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
10:01 EDTABBVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:04 EDTABBVAbbVie initiated with a Buy at SunTrust
Subscribe for More Information
July 17, 2015
09:04 EDTABBVAbbVie granted FDA orphan status for Viekira Pak in pediatric patients
Subscribe for More Information
08:06 EDTABBVAbbVie, C2N Diagnostics announce orphan drug designation of C2N-8E12
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use